Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate.
To explore herpes zoster (HZ) rates, and live zoster vaccine (LZV) safety, in a subset of patients with rheumatoid arthritis (RA) who received LZV before tofacitinib ± methotrexate (MTX), or adalimumab (ADA) + MTX, in ORAL Strategy. ORAL Strategy (NCT02187055) was a 1-year, Phase 3b/4, randomized triple-dummy, active-comparator-controlled study. MTX-inadequate responder patients received tofacitinib 5 mg BID, tofacitinib 5 mg BID + MTX, or ADA 40 mg every other week + MTX (1:1:1 randomization). Eligible patients aged ≥50 years could opt to receive LZV 28 days before initiating study treatment. HZ incidence rates (IR; patients with events per 100 patient-years) were calculated. Opportunistic HZ infections (multidermatomal/disseminated), serious HZ events, and LZV-related adverse events, were monitored. In ORAL Strategy, 216/1146 patients (18.8%) received LZV. Overall, 18 patients (1.6%) developed HZ (vaccinated: n=3; non-vaccinated: n=15). HZ IRs (95% CI) were 1.1 (0.3, 2.9), 2.3 (1.0, 4.6), and 1.7 (0.6, 3.7) for tofacitinib monotherapy, tofacitinib + MTX, and ADA + MTX, respectively, and were generally similar between vaccinated and non-vaccinated patients. Three multidermatomal, one disseminated, and two serious HZ events occurred. No vaccinated patients had zoster-like lesions within 42 days of vaccination; one patient had vaccination-site erythema. LZV was well tolerated, and HZ IRs were generally similar between treatment groups and vaccinated versus non-vaccinated patients. However, ORAL Strategy was not powered for comparisons between vaccinated and non-vaccinated patients as <20% of all patients were vaccinated. Furthermore, LZV has been shown to be effective only in around 50% of individuals. This article is protected by copyright. All rights reserved.